Brussels and Atlanta, June 12, 2025 –

布鲁塞尔和亚特兰大，2025年6月12日 –

UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics manufacturing facility in the United States. The project is expected to serve UCB’s growing number of patients in the U.S., while delivering a total estimated economic impact of approximately $5 billion.

优时比（UCB），一家专注于改善重症患者生活的全球生物制药公司，今天宣布计划在美国投资建设一座全新的、最先进的生物制品生产设施。该项目预计将服务于美国日益增长的患者群体，同时带来总计约50亿美元的预计经济影响。

UCB is also continuing to scale up its partnerships with U.S. CMOs to ensure the support for the production of its growth drivers and future pipeline..

UCB还继续扩大与美国CMO的合作伙伴关系，以确保支持其增长驱动因素和未来产品线的生产。

UCB’s growing footprint in the United States reflects our long-term commitment to delivering scientific innovation, economic impact, and sustainable healthcare value. Since 2017, our U.S. workforce has expanded by 73% to around 2,000 employees, underpinned by $4.5 billion in acquisitions and capital investments that have strengthened our innovation capabilities and infrastructure.

优时比在美国不断扩大的业务版图体现了我们对科学创新、经济影响和可持续医疗价值的长期承诺。自2017年以来，我们的美国员工人数增长了73%，达到约2000人，这得益于45亿美元的收购和资本投资，进一步增强了我们的创新能力与基础设施。

Over this time, we have achieved 15 FDA approvals or indication expansions—eight of which came in just the past two years— delivering meaningful advances in care for people living with severe diseases..

在这段时间内，我们已经获得了15项FDA批准或适应症扩展——其中八项仅在过去两年内获得——为患有严重疾病的患者提供了有意义的治疗进步。

The planned U.S. manufacturing facility marks a key advancement in UCB’s strategic ambition: it brings us closer to one of our fastest-growing markets and supports a more resilient and sustainable supply chain – while ensuring our global manufacturing capacity keeps pace with our innovation pipeline and prepare for the growth that lies ahead..

计划中的美国制造工厂标志着UCB战略目标的关键进展：它让我们更接近我们增长最快的市场之一，同时支持了更具弹性和可持续性的供应链——确保我们的全球制造能力与创新管线保持同步，并为未来的发展做好准备。

“At UCB, we are guided by a clear purpose—to create value for patients now and into the future,” said UCB’s CEO Jean-Christophe Tellier. “This investment reflects our growing impact in the US and our ambition to bring our forthcoming pipeline to patients around the world. By expanding our biologics manufacturing footprint, we’re not only reinforcing our global supply chain—we’re also contributing to the vitality of biomedical innovation, high-skilled jobs, and long-term economic impact in the US.” .

“在优时比，我们有一个明确的目标——为患者创造当下和未来的价值，”优时比首席执行官Jean-Christophe Tellier表示。“这项投资反映了我们在美国日益增长的影响力，以及我们将即将推出的产品管线带给全球患者的雄心。通过扩大我们的生物制品生产规模，我们不仅加强了全球供应链，还推动了生物医药创新、高技能就业机会，并对美国经济产生长期影响。”

The new facility is expected to create around 300 permanent, highly skilled direct jobs in biologics manufacturing and more than  500 jobs during construction. UCB is currently undertaking a comprehensive feasibility study to determine the ideal U.S. location, with a focus on regions that offer strong talent pipelines and innovation ecosystems..

新工厂预计将在生物制品制造领域创造约300个永久性的高技能直接工作岗位，并在建设期间创造500多个工作岗位。UCB目前正在进行一项全面的可行性研究，以确定理想的美国厂址，重点关注那些拥有强大人才储备和创新生态系统的地区。

This latest investment will not only support future medicine delivery—it will also generate significant value across communities through increased economic activity, partnerships, and job creation.

这项最新的投资不仅将支持未来的药物输送——它还将通过增加经济活动、伙伴关系和就业创造，在各个社区产生巨大的价值。

About UCB

关于UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024.

优时比公司（UCB），总部位于比利时布鲁塞尔（www.ucb.com），是一家全球生物制药公司，专注于发现和开发创新药物及解决方案，以改变免疫系统或中枢神经系统严重疾病患者的生活。该公司在约40个国家拥有9000多名员工，并于2024年实现了61亿欧元的收入。

UCB is listed on Euronext Brussels (symbol: UCB). .

UCB在布鲁塞尔泛欧交易所上市（股票代码：UCB）。

For more information

更多信息请参阅

Investor Relations

投资者关系

Antje Witte

安特耶·维特

Investor Relations, UCB

投资者关系，UCB

T +32.2.559.9414

电话：+32.2.559.9414

Antje.witte@ucb.com

安特耶·维特@ucb.com

Global Communications

全球通讯

Laurent Schots

劳伦特·肖茨

Media Relations, UCB

媒体关系，UCB

T+32.2.559.9264

T+32.2.559.9264

Laurent.schots@ucb.com

Laurent.schots@ucb.com

Forward looking statements

前瞻性声明

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management.

本文件包含前瞻性陈述，包括但不限于包含“潜在”、“相信”、“预期”、“预计”、“意图”、“计划”、“寻求”、“估计”、“可能”、“将”、“继续”等词语及类似表达的陈述。这些前瞻性陈述基于管理层当前的计划、估计和信念。

All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

所有声明，除历史事实声明之外，均可能被视为前瞻性声明，包括收入、营业利润率、资本支出、现金、其他财务信息、预期的法律、仲裁、政治、监管或临床结果或实践以及其他此类估计和结果。

By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document..

由于此类前瞻性陈述的性质，其并不保证未来的表现，并且受到已知和未知的风险、不确定性及假设的影响，这些因素可能导致UCB的实际结果、财务状况、业绩或成就，或行业结果，与本文件中包含的此类前瞻性陈述所明示或暗示的任何未来结果、业绩或成就存在重大差异。

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring,  retention and compliance of its employees.

可能导致此类差异的重要因素包括但不限于：战争、疫情和恐怖主义的全球蔓延及影响，总体地缘政治环境，气候变化，总体经济、商业和竞争状况的变化，无法获得必要的监管批准或在可接受的条款或预期时间内获得批准，与研发相关的成本，UCB在研产品或开发中产品的前景变化，未来司法裁决或政府调查的影响，安全性、质量、数据完整性或制造问题，供应链中断和业务连续性风险；潜在或实际的数据安全和隐私泄露，或我们信息技术系统的中断，产品责任索赔，对产品或候选产品专利保护的挑战，来自其他产品（包括生物类似药或颠覆性技术/商业模式）的竞争，法律法规的变化，汇率波动，税法及其执行的变动或不确定性，以及员工的招聘、留任和合规问题。

There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans.

无法保证在研发管线中会发现或识别出新的候选产品，也无法保证现有产品的新增适应症能够被开发并获得批准。从概念到商业化产品的推进过程充满不确定性；临床前结果不能保证候选产品在人体中的安全性和有效性。

So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpr.

到目前为止，人体的复杂性无法在计算机模型、细胞培养系统或动物模型中重现。完成临床试验和获得产品上市监管批准的时间在过去有所不同，UCB预计会有类似的不确定性。

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise.

鉴于这些不确定性，公众被提醒不要对这些前瞻性陈述给予任何过度依赖。这些前瞻性陈述仅在本文档的日期作出，且并未反映上述不断演变的事件或风险以及任何其他不利因素的潜在影响，除非另有说明。

The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB..

公司将继续认真跟进事态发展，评估这些事件对UCB的财务影响（如有）。

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations..

UCB明确表示，除非适用法律法规要求，否则不承担更新本文件中任何前瞻性声明的义务，无论这些声明是用于确认实际结果，还是用于报告或反映与其相关的任何变化，或任何基于此类声明的事件、条件或情况的变化。